ClinicalTrials.gg
Not yet recruitingNCT07538791PRRT-PGL-PHEOUpdated Nov 20, 2026

Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)

An observational study in Pheochromocytomas and Paragangliomas, sponsored by Azienda USL Reggio Emilia - IRCCS. Not yet recruiting at 10 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Azienda USL Reggio Emilia - IRCCS · Observational

How we know

Updated Nov 20, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
210
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter retrospective Italian study evaluates the efficacy and safety of PRRT in patients with advanced, unresectable or metastatic pheochromocytomas and paragangliomas (PPGL). Data from \~210 patients treated between 2000 and 2024 will be analyzed. The primary endpoint is disease control rate (DCR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), and prognostic factors.

Read the detailed description

Pheochromocytomas (PHEO) and paragangliomas (PGL), collectively referred to as PPGL, are rare neuroendocrine tumors, sometimes secreting catecholamines, with variable clinical presentations and a risk of advanced/metastatic disease. In patients not eligible for curative treatment or with progressive disease, multimodal strategies may be used, including systemic and radiometabolic therapies, although shared therapeutic algorithms are difficult to define. In particular, in PPGL with somatostatin receptor expression documented by functional imaging, PRRT (Peptide Receptor Radionuclide Therapy) represents a therapeutic option used in an experimental/off-label setting, within authorized clinical protocols or clinical trials, as reported in the literature. Between 2000 and 2024, several centers in Italy treated PPGL patients with PRRT using different regimens (radionuclide, number of cycles, and timing), depending on experimental protocols, technological availability, and clinical characteristics. This heterogeneity, combined with the rarity of the disease, highlights the relevance of a structured national collection of real-world data to describe the efficacy and safety of PRRT in this setting. This is a retrospective, multicenter, non-profit observational pharmacological study including adult patients (≥18 years) with documented PPGL and advanced/unresectable or metastatic disease who received at least one cycle of PRRT within the study period. Patients must have available essential data to document treatment exposure and outcomes, including at least one post-treatment evaluation for disease control and minimum data for progression-free survival assessment.

PRRT exposure includes treatments administered within completed clinical trials or authorized protocols at participating centers. Data collected will include type of radionuclide(s), number of planned and administered cycles, treatment intervals, and reasons for treatment modifications or discontinuation, where available.

02

Conditions studied

  • Pheochromocytomas
  • Paragangliomas

Keywords

  • PPGL
  • PRRT
  • PHEO
  • PGL
  • Somatostatin receptors
  • Peptide Receptor Radionuclide Therapy
03

In context

Pheochromocytoma

158 studies on the registry are indexed under Pheochromocytoma; 57 are open to participants now.

This study's planned enrollment of 210 is above the median of 184 across 56 observational studies indexed under Pheochromocytoma.

Browse Pheochromocytoma studies →

Lead sponsor

Azienda USL Reggio Emilia - IRCCS is the lead sponsor of 93 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with sporadic or hereditary paraganglioma and pheochromocytoma (PPGL) with unresectable or metastatic disease, treated with peptide receptor radionuclide therapy (PRRT).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of pheochromocytoma or paraganglioma (PPGL) (sporadic or hereditary forms) with unresectable or disease.
  • Treatment with peptide receptor radionuclide therapy (PRRT) administered with ⁷⁷Lu and/or ⁹⁰Y (including combination regimens), with t0 (first PRRT administration) between January 1, 2000 and February 28, 2024.
  • Availability of essential data required by the protocol to document exposure (PRRT) and outcomes, including: PRRT start date (t0) and treatment details (radioisotope(s), number of cycles and/or cycles actually administered, intervals when available), At least one post-treatment evaluation suitable for determining disease control rate (DCR) (morphological imaging by CT/MRI ± functional imaging by PET/CT, and available clinical data), Follow-up information suitable for determining progression-free survival (PFS) within the predefined time window.
  • Availability of follow-up up to 12 months from end of treatment (EoT), or documentation of progression and/or death occurring within 12 months.
  • Required data and source documents are available at the enrolling center or obtainable from other Italian centers (e.g., PRRT-administering center or centers performing imaging/evaluations) through formal data transfer agreements (e.g., DTA) in compliance with applicable regulations.
  • Privacy/consent requirements (general framework):

For living and contactable patients, consent for personal data processing will be managed according to the requirements/assessment of the Ethics Committee.

For deceased or non-contactable patients after reasonable documented efforts, inclusion may occur without consent, as it falls under situations of "impossibility to inform the subjects," in accordance with applicable regulations (Article 110 of the Italian Privacy Code and subsequent amendments), subject to Ethics Committee evaluation/opinion and implementation of appropriate safeguards.

Exclusion criteria

Exclusion Criteria:

  • Patients who did not receive at least one cycle of peptide receptor radionuclide therapy (PRRT).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
210 participants (estimated)
Patient registry
No

Groups and cohorts

  • MONO 177Lu

    Patients treated with PRRT using ¹⁷⁷Lu only.

    Radiation: Peptide Receptor Radionuclide Therapy (PRRT)

  • MONO 90Y

    Patients treated with PRRT using ⁹⁰Y only.

    Radiation: Peptide Receptor Radionuclide Therapy (PRRT)

  • TANDEM 177Lu + 90Y

    Patients treated with PRRT using a combination (sequential or concomitant) of ¹⁷⁷Lu and ⁹⁰Y.

    Radiation: Peptide Receptor Radionuclide Therapy (PRRT)

Interventions

  • RadiationPeptide Receptor Radionuclide Therapy (PRRT)

    PRRT with radiolabeled somatostatin analogues (¹⁷⁷Lu and/or ⁹⁰Y), according to clinical practice.

06

What researchers measure

Primary outcomes

  1. Disease Control Rate (DCR)

    To describe the effectiveness of PRRT in terms of disease control rate (DCR) in the overall population and by line of treatment (early vs late).

    Time frame: baseline, 12 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    To evaluate progression-free survival (PFS) after PRRT in the overall population and by line of treatment (early vs late).

    Time frame: baseline, 12 months

  2. Overall Survival (OS)

    To evaluate overall survival (OS) at 1 year after completion of PRRT, including analysis by response category (complete response, partial response, stable disease, progressive disease).

    Time frame: 12 months

07

Study locations

10 sites
08

References and documents

Publications

  • Su D, Yang H, Qiu C, Chen Y. Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis. Front Oncol. 2023 Jul 6;13:1141648. doi: 10.3389/fonc.2023.1141648. eCollection 2023. PubMed 37483516 ↗
  • Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul. 2020 Jun 3;54(2):159-168. doi: 10.14744/SEMB.2020.18794. eCollection 2020. PubMed 32617052 ↗
  • Saavedra T JS, Nati-Castillo HA, Valderrama Cometa LA, Rivera-Martinez WA, Asprilla J, Castano-Giraldo CM, Sanchez S L, Heredia-Espin M, Arias-Intriago M, Izquierdo-Condoy JS. Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment. Front Endocrinol (Lausanne). 2024 Dec 13;15:1433582. doi: 10.3389/fendo.2024.1433582. eCollection 2024. PubMed 39735644 ↗
  • Cascon A, Calsina B, Monteagudo M, Mellid S, Diaz-Talavera A, Curras-Freixes M, Robledo M. Genetic bases of pheochromocytoma and paraganglioma. J Mol Endocrinol. 2023 Jan 24;70(3):e220167. doi: 10.1530/JME-22-0167. Print 2023 Apr 1. PubMed 36520714 ↗
  • Welander J, Soderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011 Dec 1;18(6):R253-76. doi: 10.1530/ERC-11-0170. Print 2011 Dec. PubMed 22041710 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Aug 2026 → Dec 2026 and primary completion Aug 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 20, 2026
StartEst.
Dec 2026was Aug 2026
Primary completionEst.
Apr 2027was Aug 2026
CompletionEst.
Apr 30, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 30, 2026→Dec 2026
Nov 20, 2026
Primary completion
Aug 30, 2026→Apr 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Start date Aug 30, 2026→Dec 2026
    Primary completion Aug 30, 2026→Apr 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07538791
Lead sponsor
Azienda USL Reggio Emilia - IRCCS
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Dec 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Angelina Filice, MD
Contact
angelina.filice@ausl.re.it
0522 296313
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion